Therapeutics News and Research

RSS

Argos' AGS-004 shows feasibility in in vitro models to generate DC from viremic patients

Argos Therapeutics announced today that its Arcelis HIV immunotherapy, AGS-004, showed feasibility in in vitro models to generate fully functional dendritic cells (DC) from viremic patients.

13 Dec 2010

Positive preliminary results from tivozanib-paclitaxel combination Phase 1b trial in metastatic breast cancer

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preliminary results from an ongoing Phase 1b clinical trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol®), a standard chemotherapy regimen, in patients with metastatic breast cancer.

10 Dec 2010

Celulas Genetica to submit international patent application for Rutherford Procedure

Emerging Healthcare Solutions, Inc. announced today that its newly acquired biotechnology division Celulas Genetica will submit an international patent application for the Rutherford Procedure, a revolutionary new stem-cell treatment for liver disease.

10 Dec 2010

PharmaDirections congratulates Orexigen on FDA Advisory approval for Contrave

PharmaDirections congratulates Orexigen Therapeutics on achieving FDA Advisory Board approval for their anti-obesity drug Contrave™. PharmaDirections is proud to have been Orexigen's pharmaceutical development partner and to have developed and produced the first Contrave™ product to undergo full clinical development.

10 Dec 2010

Acorda initiates enrollment in GGF2 Phase 1 clinical trial in patients with heart failure

Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of Glial Growth Factor 2 (GGF2). Acorda is collaborating with the Vanderbilt University Heart and Vascular Institute to conduct this Phase 1 single-dose trial in patients with heart failure.

9 Dec 2010

Nacalai to distribute Techulon's Glycofect Transfection Reagent platform products in Japan

Techulon Inc., an early stage life sciences company has signed an agreement with Nacalai USA, Inc. and its parent company Nacalai Tesque, Inc. for distribution of its Glycofect Transfection Reagent platform products in Japan. Glycofect is a polymeric transfection reagent designed to be particularly effective in primary cells of therapeutic interest. It is being used by government, university and corporate laboratories around the world for advanced research towards better understanding of cell biology and for development of new cell-based therapeutics.

9 Dec 2010

Health care systems inadequate for managing acute GI hemorrhage outside of normal hours

Patients treated by Welsh hospitals for upper gastrointestinal (GI) bleeding were 41% more likely to die if they were admitted on a public holiday and 13% more likely if it was at the weekend, according to research in the January issue of Alimentary Pharmacology and Therapeutics.

9 Dec 2010

Rexahn presents data from Serdaxin Phase IIa study at 49th ACNP Annual Meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the presentation of data from its proof of concept study with lead CNS compound Serdaxin® at the 49th American College of Neuropsychopharmacologists (ACNP) Annual Meeting, held in Miami Beach, FL, December 5-9, 2010 at the Fountainbleau Resort.

9 Dec 2010

VIRxSYS presents study results of VRX1116 at HIV DART 2010

VIRxSYS Corporation, a privately held company developing vaccines and RNA therapies, today presented results from a study of VRX1116 at HIV DART 2010 in Los Cabos, Mexico, showing that vaccinated monkeys challenged with highly pathogenic simian immunodeficiency virus achieve sustained viral load reduction, preservation of the immune system and increased survival compared to controls.

9 Dec 2010

OMT announces new human antibody platform using genetically engineered rats expressing human antibodies

Open Monoclonal Technology, Inc. (OMT) today announced its new human antibody platform using the first genetically engineered rats expressing a human antibody repertoire. The company, which also created the first targeted knockout rats in 2009, is now cross-breeding the knockout animals with the rats expressing human antibodies to finalize its platform.

9 Dec 2010

Anchor Therapeutics announces publication describing pepducin technology as novel approach to target GPCR

Anchor Therapeutics today announced the publication of new research in the Proceedings of the National Academy of Sciences USA. The paper describes the identification and characterization of a pepducin-based allosteric agonist that targets CXCR4, a chemokine G protein-coupled receptor found on hematopoietic stem cells and other bone marrow-derived cells.

9 Dec 2010

NIH to create new translational science center

National Institutes of Health (NIH) Director Francis Collins on Tuesday announced the agency is moving forward on plans to create a new research center focused on translational science, after NIH's advisory board voted to create the new center, Science's "Science Insider" blog reports (Kaiser, 12/7).

9 Dec 2010

UBC's new formulation of Amphotericin B for Visceral Leishmaniasis remains stable in tropical climates

A new formulation of Amphotericin B (AmB) developed by University of British Columbia researchers has been shown to be stable in tropical climates and effective in treating Visceral Leishmaniasis (VL) in mouse models.

8 Dec 2010

North Tees and Hartlepool NHS Foundation Trust pioneer novel technique for breast reconstruction

Surgeons at North Tees and Hartlepool NHS Foundation Trust are pioneering a novel technique for breast reconstruction that has the potential to make a huge difference to the lives of women affected by breast cancer.

8 Dec 2010

Small molecules show promise in protecting brain cells against nerve-degenerative diseases

Investigators at Southern Methodist University and The University of Texas at Dallas have discovered a family of small molecules that shows promise in protecting brain cells against nerve-degenerative diseases such as Parkinson's, Alzheimer's and Huntington's, which afflict millions.

8 Dec 2010

IEEE members are transforming the future of medicine and healthcare

Members of IEEE, the world's largest technical professional association, are advancing the application of engineering sciences and technology with medicine and biology to make healthcare personal again.

8 Dec 2010

New technique may help develop novel treatments for brain diseases

Scientists have created a way to isolate neural stem cells - cells that give rise to all the cell types of the brain - from human brain tissue with unprecedented precision, an important step toward developing new treatments for conditions of the nervous system, like Parkinson's and Huntington's diseases and spinal cord injury.

8 Dec 2010

Children's Hospital LA investigators elected into the Society for Pediatric Research

Three investigators from The Saban Research Institute of Children's Hospital Los Angeles have been elected into the prestigious Society for Pediatric Research. Their election to this Society represents peer recognition of their research achievements in pediatrics.

8 Dec 2010

Cephalon, Mesoblast to develop, commercialize novel adult MPC therapeutics

Cephalon, Inc. and Mesoblast Limited, today announced they have entered into a strategic alliance to develop and commercialize novel adult Mesenchymal Precursor Stem Cell therapeutics for degenerative conditions of the cardiovascular and central nervous systems.

8 Dec 2010

BioMimetic Therapeutics to assess safety, clinical utility of Augment Rotator Cuff Graft

BioMimetic Therapeutics, Inc. today announced it initiated enrollment in a pilot clinical trial to assess the safety and clinical utility of AugmentTM Rotator Cuff Graft for the repair of large rotator cuff tears. The randomized, controlled pilot trial is expected to include enrollment of up to 30 patients.

8 Dec 2010

Therapeutics News and Research

Argos' AGS-004 shows feasibility in in vitro models to generate DC from viremic patients

Positive preliminary results from tivozanib-paclitaxel combination Phase 1b trial in metastatic breast cancer

Celulas Genetica to submit international patent application for Rutherford Procedure

PharmaDirections congratulates Orexigen on FDA Advisory approval for Contrave

Acorda initiates enrollment in GGF2 Phase 1 clinical trial in patients with heart failure

Nacalai to distribute Techulon's Glycofect Transfection Reagent platform products in Japan

Health care systems inadequate for managing acute GI hemorrhage outside of normal hours

Rexahn presents data from Serdaxin Phase IIa study at 49th ACNP Annual Meeting

VIRxSYS presents study results of VRX1116 at HIV DART 2010

OMT announces new human antibody platform using genetically engineered rats expressing human antibodies

Anchor Therapeutics announces publication describing pepducin technology as novel approach to target GPCR

NIH to create new translational science center

UBC's new formulation of Amphotericin B for Visceral Leishmaniasis remains stable in tropical climates

North Tees and Hartlepool NHS Foundation Trust pioneer novel technique for breast reconstruction

Small molecules show promise in protecting brain cells against nerve-degenerative diseases

IEEE members are transforming the future of medicine and healthcare

New technique may help develop novel treatments for brain diseases

Children's Hospital LA investigators elected into the Society for Pediatric Research

Cephalon, Mesoblast to develop, commercialize novel adult MPC therapeutics

BioMimetic Therapeutics to assess safety, clinical utility of Augment Rotator Cuff Graft

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News